Oligometastatic cancer is defined as a clinical state of metastatic disease that is limited to “oligo” or few metastatic lesions as identified by imaging. Conceptualized in the 1990s by Drs. Hellman and Weichselbaum, it has now become an accepted condition in the natural history of most solid malignancies
Editorial on Oligometastasis- Fallacy or Real Deal?
Defining the role of curative local therapy in oligometastatic cancer: a new era
Review Article on Oligometastasis- Fallacy or Real Deal?
Oligometastases: history of a hypothesis
Technical challenges of linac-based stereotactic ablative body radiotherapy: short review for non-radiation oncologists
Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy
Oligometastatic breast cancer: where are we now and where are we headed?—a narrative review
A narrative review of oligometastatic prostate cancer—an evolving paradigm
The multidisciplinary management of oligometastases from colorectal cancer: a narrative review
Treatment paradigms for oligometastatic pediatric cancers: a narrative review with a focus on radiotherapy approaches
Limited brain metastases: a narrative review
The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review
A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions
Disclosure:
The series “Oligometastasis- Fallacy or Real Deal?” was commissioned by the editorial office, Annals of Palliative Medicine without any sponsorship or funding. Simon Lo, Michael Milano, Tithi Biswas and Charles B. Simone, II served as the unpaid Guest Editors for the series.